Clinical trial
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With…
NCT00450827 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00450827 |
|---|---|
| Title | Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma |
| Official title | Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological, Procedure, Radiation |
| Interventions | bevacizumab, filgrastim, autologous hematopoietic stem cell transplantation, iodine I 131 monoclonal antibody 3F8 |
| Enrollment | 25 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Mar 22, 2007 |
| Last update posted | Sep 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: